Fitzgerald Joseph Michael

EVP Cardiology Fitzgerald sells 50,000 shares (50.0K shares) for $4,973,337.63 across 3 transactions at BSX

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, executed 3 separate sales totaling 50,000 shares for $4,973,337.63 on November 3, 2025, reducing his holdings by 21.9% from 228,342 to 178,342 shares. The sales occurred at a blended average price of $99.47, slightly above the current price of $98.84, within the 52-week range of $83.62–$108.14. Fitzgerald's recent pattern at Boston Scientific shows 5 prior trades since August, predominantly sells, with mixed near-term outcomes: his prior 2 October sells posted 30-day gains of +2.4% and +1.8%, while his September sales showed 30-day declines of -9.1% and -8.3%. His cross-ticker track record across all tickers shows 12 prior sells with an average 90-day return of +3.7% and a 37.50% well-timed rate, indicating his recent sell patterns have not consistently preceded stock declines. This large concentrated reduction in a material position occurs without scheduled trading plan disclosure in the filing, though the magnitude and frequency of recent transactions warrant monitoring for strategic context.

EVP of Cardiology sells 50,000 BSX shares in 2 transactions (8,245 @ $98.91, 41,755 @ $98.38) for $4,923,326.81

Fitzgerald Joseph Michael, EVP & Group Pres of Cardiology at Boston Scientific, executed 2 separate sales totaling 50,000 shares on 2025-10-01 for a blended average price of $98.47, reducing his holdings by -21.9% to 178,342 shares. The transaction occurred as the stock trades at $95.85, down -11.4% from its 52-week high of $108.14 and down -9.2% over the past 30 days. Across his open-market history at this ticker, his 5 prior trades show a 50% well-timed rate at the 90-day mark for sells (1 of 2 prior measurable sells were timed to precede declines), and his cross-ticker track record shows a 28.57% well-timed rate on sells, with most recent outcomes at BSX (two September sales) not yet measurable. The company fundamentals remain solid with $5.1B quarterly revenue and +17.6% annual revenue growth, though the elevated P/E of 56.72 and recent stock weakness merit observation alongside this substantial equity reduction by a division president.

BSX EVP Cardiology sells 50,000 shares at $104.89–$105.85 for $5.3M, reducing stake by 21.9% to 178.3K shares

Fitzgerald Joseph Michael, EVP & Group President of Cardiology, executed two separate sales totaling 50,000 shares for $5,271,416.44 on 2025-09-02 at blended average price $105.43—near the 52-week high of $107.76. This represents a 21.9% reduction in his holdings. His prior five trades at BSX show a mixed pattern: one of three measurable 90-day outcomes was well-timed, with the most recent sell on 2025-08-01 posting +0.8% in 30 days. The company trades at a P/E of 63.63 with annual revenue growth of +17.6% and $795.0M net income on $5.1B quarterly revenue. The current stock price ($107.53) has declined 0.2% from the 52-week high but risen 4.6% over 90 days and 0.7% over 30 days, indicating strength in the broader trend despite proximity to yearly highs.

EVP Fitzgerald Joseph Michael sold 50,000 BSX shares at $104.63; holdings reduced 21.9% to 178,342 shares.

Fitzgerald Joseph Michael, EVP & Group President of Cardiology at Boston Scientific, executed a substantial open-market sale of 50,000 shares (50.0K shares) at $104.63, reducing his stake by 21.9% to 178,342 shares. The $5,231,670.00 ($5.2M) transaction occurs in a stock near its 52-week high ($107.76), with the current price at $106.79. Among his prior sales at Boston Scientific, his timing record is mixed: 1 of 3 prior sales at this ticker were well-timed at the 90-day mark, and his cross-ticker sell track record shows a 20.00% well-timed rate with average 90-day returns of +7.8% following his prior sales—indicating the stock typically rose after his exits. The company reports strong fundamentals (annual revenue growth of +17.6%, net income of $795,000,000.00, and market cap of $158,236,256,994.86), though a P/E of 63.19 reflects premium valuation. This reduction of a significant executive position warrants monitoring for any broader strategic shifts, though the magnitude and timing relative to valuation should be evaluated in the context of any scheduled plan disclosures.

EVP Fitzgerald sells 50,000 BSX shares at $106.97; stock now $103.63, -3.5% from 52w high

Fitzgerald Joseph Michael, EVP & Group Pres Cardiology, sold 50,000 shares (50.0K shares) at $106.97 on 2025-07-01 for $5,348,315.00, reducing his holdings by -21.9% from 228,342 to 178,342 shares. The sale occurred near the 52-week high of $107.41, with the stock now at $103.63 (-3.5% from peak). His same-ticker history at BSX shows 1 of 4 prior measurable trades was well-timed at the 90-day mark, with his cross-ticker track record showing a 20.00% well-timed rate on 6 prior sells, indicating mixed success in timing exit points. The fundamental backdrop remains strong: BSX reported $4.7B quarterly revenue, +17.6% annual growth, and $672.0M net income, though the elevated P/E of 75.64 reflects a premium valuation that provides context for insider reduction of holdings.

EVP Joseph Michael Fitzgerald sells 56,372 shares of BSX at $102.88; reduces stake by 24.0% to 178,342 shares

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, sold 56,372 shares for $5.8M on June 4, 2025, reducing his holdings from 234,714 to 178,342 shares—a 24.0% reduction in stake. Across his open-market history at all tickers, Fitzgerald's five prior sales averaged a 7.8% 90-day return with a 20.00% well-timed rate, meaning his sell timing has been inconsistent; at BSX specifically, he has completed five prior trades with only one proving well-timed at the 90-day mark. The stock is currently trading at $102.43, down 1.7% over 30 days and 4.0% from its 52-week high of $106.66, suggesting a pullback from recent peaks. Boston Scientific trades at a P/E of 74.77 with strong recent fundamentals (annual revenue growth of +17.6%, latest quarter revenue of $4.7B, net income of $672.0M), so the sale does not occur against deteriorating company performance but rather against a backdrop of elevated valuation and modest recent price weakness.

BSX EVP Fitzgerald bought 50 shares at $90.29, sold 20 at $89.97 on 2024-12-03 and 2024-12-10

Fitzgerald Joseph Michael executed 2 separate transactions: a purchase of 50 shares at $90.29 on 2024-12-03 ($4,514.60) and a sale of 20 shares at $89.97 on 2024-12-10 ($1,799.44), resulting in a net addition of 30 shares to his 172,863-share position. The transactions span a small price range ($90.29 to $89.97) in a stock that has risen 11.0% over 30 days and 22.0% over 90 days to a current price of $106.14, within 0.0% of its 52-week high of $106.18. Across his same-ticker history at BSX, Fitzgerald's prior 4 sales showed mixed timing outcomes: 3 of 4 sales were followed by stock appreciation at the 90-day mark (gains ranging 6.7% to 19.1%), with only 1 of 4 wells-timed at the 90-day mark. The modest transaction sizes and near-simultaneous buy-sell activity do not establish a definitive signal of insider positioning relative to BSX's recent strong momentum.

EVP Joseph Michael Fitzgerald sold 132,527 shares of BSX at $85.00 for $11.3M, reducing holdings 45.2%.

Fitzgerald, an EVP and Group President in Cardiology, sold 132,527 shares at $85.00 on 2024-10-07, reducing his holdings from 293.0K to 160.5K shares—a substantial 45.2% reduction. The transaction occurred at a price near the 52-week high of $85.84, and the stock has appreciated 5.2% over the prior 30 days and 11.3% over the prior 90 days, suggesting the sale occurred amid positive momentum. Reviewing Fitzgerald's BSX-specific prior transactions, one of his two measurable prior sales showed well-timed outcomes at the 90-day mark (the 2023-12-29 sale yielded +19.1% return post-transaction, indicating he sold before a decline). The current sale's timing relative to future price action remains unknown, but the significant reduction in personal holdings—while not definitive—merits investor monitoring given the large position size and proximity to recent highs.

EVP Cardiology Group sold 14,132 BSX shares at $80.00 on 2024-08-28; stock now at $80.67, near 52-week high.

Fitzgerald Joseph Michael, EVP & Group President of Cardiology, sold 14,132 shares (14.1K shares) of Boston Scientific at $80.00, reducing his holdings by -7.4% to 176,355 shares. The sale occurred at $80.00, and the stock currently trades at $80.67, at its 52-week high of $80.67, indicating the insider sold just before a modest further appreciation. His cross-ticker track record shows 2 prior sells with an average 90-day return of +7.4% and a 50.00% well-timed rate, while his prior trades at BSX show mixed timing results (one well-timed at -4.2% 90d return, one poorly timed at +19.1% 90d return). The company's fundamentals remain solid with $4.1B in quarterly revenue, +12.3% annual growth, and a P/E of 65.06, though the high valuation may warrant attention given the insider's discretionary reduction.